SCHEMBL369867

SCHEMBL369867

CC(C)(C)OC(=O)Cc1nn(Cc2nc3ccccc3n2C(=O)OC(C)(C)C)c(=O)c2nccnc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.42
MAP4K1 Q92918 2/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 4/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
PDE10A Q9Y233 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
NR1H2 P55055 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CNR2 P34972 2/20 0.33
MAOA P21397 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
OGFRL1 Q5TC84 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10065363 0.93 AKR1B1 (0.51) AKR1B1MAP4K1PDE10AKMT2A
SCHEMBL18265843 0.91 AKR1B1 (0.39) AKR1B1MAP4K1KDM4EALDH1A1NPC1
SCHEMBL15206300 0.89 AKR1B1 (0.55) AKR1B1KDM4EALDH1A1NPC1RAB9A
SCHEMBL367953 0.87 AKR1B1 (0.41) AKR1B1
SCHEMBL29915596 0.80 AKR1B1 (0.43) AKR1B1
SCHEMBL19140389 0.79 AKR1B1 (0.38) AKR1B1CNR2
SCHEMBL360788 0.78 AKR1B1 (0.53) AKR1B1
SCHEMBL368658 0.75 AKR1B1 (0.72) AKR1B1NPC1RAB9A
SCHEMBL19140537 0.75 AKR1B1 (0.53) AKR1B1KDM4EALDH1A1NPC1RAB9A
SCHEMBL14838247 0.72 CYP1A2 (0.47) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180907-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2024-06-06 US disclosed
US-11730737-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-08-22 US disclosed
US-11730737-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-08-22 US disclosed
EP-4124620-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2023-02-01 EP disclosed
EP-4124620-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2023-02-01 EP disclosed
US-11529349-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-12-20 US disclosed
EP-3597650-B1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF UNIV COLUMBIA (US) 2022-09-07 EP disclosed
US-20200289512-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2020-09-17 US disclosed
US-20200268755-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-08-27 US disclosed
US-10639306-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-05 US disclosed
US-9650383-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-05-16 US disclosed
EP-2593456-B1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF UNIV COLUMBIA (US) 2016-11-30 EP disclosed
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-12 US disclosed
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-12 US disclosed
US-8916563-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-12-23 US disclosed
US-8916563-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-12-23 US disclosed
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-08-29 US disclosed
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-08-29 US disclosed
EP-2593456-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2013-05-22 EP disclosed
WO-2012009553-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180907-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 AKR1B1 2/4885MAP4K1 1333/4885KDM4E 1917/4885
US-20200268755-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 AKR1B1 2/4885MAP4K1 1333/4885KDM4E 1917/4885
US-20200289512-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 AKR1B1 2/4885MAP4K1 1333/4885KDM4E 1917/4885
US-11529349-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 AKR1B1 2/4885MAP4K1 1333/4885KDM4E 1917/4885
US-10639306-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 AKR1B1 2/4885MAP4K1 1333/4885KDM4E 1917/4885
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 AKR1B1 2/4885MAP4K1 1333/4885KDM4E 1917/4885
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 AKR1B1 2/4885MAP4K1 1333/4885KDM4E 1917/4885
US-11730737-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 AKR1B1 2/4885MAP4K1 1333/4885KDM4E 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.